Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 12/20 | 0.50 |
| ▸ | HTR2C | P28335 | 9/20 | 0.48 |
| ▸ | HTR2B | P41595 | 9/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
| ▸ | HTR1E | P28566 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR1F | P30939 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25240749 | 0.88 | HTR1A (0.52) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25029851 | 0.86 | HTR1A (0.72) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25008690 | 0.85 | HTR1A (0.50) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25029867 | 0.83 | HTR1A (0.57) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL31077923 | 0.82 | HTR1A (0.56) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25288798 | 0.82 | HTR1A (0.56) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25024712 | 0.82 | HTR1A (0.50) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL24460448 | 0.82 | HTR1A (0.50) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL24460460 | 0.82 | HTR1A (0.50) | HTR1AHTR2AHTR2CHTR2BHTR1D | |
| SCHEMBL25748357 | 0.82 | HTR6 (0.46) | HTR1AHTR2AHTR2CHTR2BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2025-02-20 | — | — | US | disclosed |
| EP-4452937-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-117897376-A | Heterocyclic compounds and process for preparing same | 光明智慧生物科学公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4347561-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | Bright Minds Biosciences Inc. (CA) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230051548-A1 | NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| WO-2022246554-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | BRIGHT MINDS BIOSCIENCES INC. (CA) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022104475-A1 | NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | MAGICMED INDUSTRIES INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | HTR1A 185/4885HTR2A 94/4885HTR2C 23/4885 |
| US-20230051548-A1 | NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | PNMT, HTR1B, HTR2B | HTR1A 36/4885HTR2A 34/4885HTR2C 8/4885 |
| US-20250059217-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | OPRL1, OPRK1, CNR2 | HTR1A 306/4885HTR2A 413/4885HTR2C 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.